文献速递腹部技术与安全PETCT

18F-FDG PET/CT在肝样腺癌临床评估中的作用

The role of 18F-FDG PET/CT in the clinical evaluation of hepatoid adenocarcinoma.
PubMed 文献 · Abdom Radiol (NY) · 2026-06-29

本研究回顾性纳入66例病理确诊肝样腺癌患者,共71次18F-FDG PET/CT检查,其中44次用于治疗前分期。结果显示胃为最常见原发部位,肝为最常见转移部位。18F-FDG PET/CT发现隐匿转移,使36.36%初诊患者及43.75%术后患者调整治疗策略。

要点

  • 肝样腺癌多数初诊时已存在远处转移,即使T1期也可发生远处转移。
  • 胃是肝样腺癌最常见原发部位,肝是最常见转移器官。
  • PET代谢参数与血清AFP、CEA水平无显著相关性。

核心结论

  • 18F-FDG PET/CT通过检出隐匿转移,有助于肝样腺癌的准确分期并指导临床管理。

研究设计与样本

  • 回顾性研究,纳入66例病理确诊肝样腺癌患者,共行71次18F-FDG PET/CT检查。
  • 检查用途包括治疗前分期44次、术后随访16次、非手术治疗后疗效评估11次。

关键影像表现/征象

  • 44例初诊肝样腺癌中,胃为最常见原发肿瘤部位,占59.1%(26/44)。
  • 除卵巢来源外,所有原发肿瘤均表现为FDG摄取增高,SUVmax中位数为9.25。
  • 54.5%(24/44)初诊患者存在远处转移,肝为最常见转移部位,占36.4%(16/44)。
  • 远处淋巴结转移占18.2%(8/44),骨转移占11.4%(5/44)。
  • T1期肿瘤中50.0%(2/4)已发生远处转移。

诊断标准与关键数值

  • 79.5%(35/44)初诊患者血清AFP水平升高。

临床应用与阅片要点

  • 18F-FDG PET/CT检查使36.36%(16/44)初诊患者临床治疗策略发生调整。
  • 18F-FDG PET/CT检查使43.75%(7/16)术后患者临床治疗策略发生调整。
  • PET代谢参数与血清AFP、CEA水平均无显著相关性(所有P>0.05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Hepatoid adenocarcinoma (HAC) is a rare malignant neoplasm arising in extrahepatic tissues and organs, and its prompt and correct diagnosis remains clinically challenging. 18F-FDG PET/CT is widely utilized for the evaluation of various tumor types, relevant data regarding its performance in HAC remain limited. The present study aimed to summarize the ¹⁸F-FDG PET/CT imaging features of HAC and to assess its clinical impact on patient management.

METHODS: A total of 66 patients with pathologically confirmed HAC underwent 71 18F-FDG PET/CT examinations. These examinations included 44 for pre-treatment staging, 16 for postoperative surveillance, and 11 for assessment of treatment response following non-surgical therapy. PET-derived metabolic parameters (SUVmax, MTV, TLG), lesion location, lymph node metastasis status, and corresponding alterations in clinical management were retrospectively collected and analyzed.

RESULTS: Among 44 patients with initial HAC, the stomach was the most common primary tumor site (26/44, 59.1%). All primary tumors, with the exception of those of ovarian origin, exhibited increased FDG uptake, with a median SUVmax of 9.25. Elevated serum alpha-fetoprotein (AFP) levels were observed in 79.5% (35/44) of patients at initial diagnosis. A majority of patients (24/44, 54.5%) presented with distant metastases at the time of initial diagnosis, where the liver was the most common metastatic site (16/44, 36.4%), followed by distant lymph nodes (8/44, 18.2%) and bone (5/44, 11.4%). Notably, 50.0% (2/4) of T1-stage tumors had already developed distant metastases. The findings of 18F-FDG PET/CT led to changes in patient diagnosis and treatment strategies: 36.36% (16/44) of newly diagnosed patients and 43.75% (7/16) of postoperative patients had their clinical treatment strategies adjusted. In addition, no significant correlations were found between PET metabolic parameters and serum levels of AFP or carcinoembryonic antigen (CEA) (all P > 0.05).

CONCLUSION: 18F-FDG PET/CT facilitates accurate staging of hepatoid adenocarcinoma by detecting occult metastases and guiding clinical management in initial diagnosis and postoperative surveillance. The most frequent primary site is the stomach, with the liver being the main metastatic organ. Importantly, 18F-FDG PET/CT findings significantly influences clinical management for patients with HAC prior to and after treatment without correlation to AFP or CEA levels.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Lin, Wang, Yan, et al. The role of 18F-FDG PET/CT in the clinical evaluation of hepatoid adenocarcinoma. Abdom Radiol (NY). 2026. PMID: 42371017. doi:10.1007/s00261-026-05651-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。